These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 19402170

  • 1. Treatment of fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Keating MJ.
    Cancer; 2009 Jul 01; 115(13):2824-36. PubMed ID: 19402170
    [Abstract] [Full Text] [Related]

  • 2. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
    Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG.
    Blood; 2011 Aug 25; 118(8):2085-93. PubMed ID: 21670470
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B, Hallek M.
    Clin Lymphoma; 2002 Jun 25; 3(1):26-35. PubMed ID: 12141952
    [Abstract] [Full Text] [Related]

  • 6. Current and emerging treatments for chronic lymphocytic leukaemia.
    Robak T, Jamroziak K, Robak P.
    Drugs; 2009 Jun 25; 69(17):2415-49. PubMed ID: 19911856
    [Abstract] [Full Text] [Related]

  • 7. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE, Rai KR, O'Brien S.
    Clin Adv Hematol Oncol; 2006 Nov 25; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [Abstract] [Full Text] [Related]

  • 8. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S, Montillo M, Ribatti D, Mirabelli R, Tedeschi A, Ricci F, Veronese S, Vacca A, Morra E.
    Haematologica; 2007 Oct 25; 92(10):1367-74. PubMed ID: 17768114
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 10. Fludarabine in chronic lymphocytic leukaemia.
    Elter T, Hallek M, Engert A.
    Expert Opin Pharmacother; 2006 Aug 15; 7(12):1641-51. PubMed ID: 16872267
    [Abstract] [Full Text] [Related]

  • 11. Antibody therapy for chronic lymphocytic leukemia.
    Christian BA, Lin TS.
    Semin Hematol; 2008 Apr 15; 45(2):95-103. PubMed ID: 18381104
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
    Lepretre S, Jäger U, Janssens A, Leblond V, Nikitin E, Robak T, Wendtner CM.
    Leuk Lymphoma; 2012 May 15; 53(5):820-9. PubMed ID: 21992675
    [Abstract] [Full Text] [Related]

  • 19. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG.
    Blood; 2011 Aug 25; 118(8):2062-8. PubMed ID: 21750315
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.
    J Clin Oncol; 2006 May 20; 24(15):2337-42. PubMed ID: 16618945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.